GNLX Stock Summary and Trading Ideas (Genelux | NASDAQ:GNLX)

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.

Genelux trades on the NASDAQ stock market under the symbol GNLX.

As of May 6, 2024, GNLX stock price climbed to $3.84 with 151,493 million shares trading.

GNLX has a beta of 1.46, meaning it tends to be more sensitive to market movements. GNLX has a correlation of 0.03 to the broad based SPY ETF.

GNLX has a market cap of $102.60 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that GNLX belongs to (by Net Assets): VTI, VXF, IWM, IWN, VTWO.

GNLX has underperformed the market in the last year with a price return of -84.4% while the SPY ETF gained +28.3%. GNLX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -60.8% and -7.0%, respectively, while the SPY returned +4.8% and +4.3%, respectively.

GNLX support price is $3.55 and resistance is $4.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GNLX stock will trade within this expected range on the day.